Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2012 (2012), Article ID 495934, 14 pages
http://dx.doi.org/10.1155/2012/495934
Research Article

Altered AKT1 and MAPK1 Gene Expression on Peripheral Blood Mononuclear Cells and Correlation with T-Helper-Transcription Factors in Systemic Lupus Erythematosus Patients

1Department of Cellular Biology and Immunology, Instituto de Parasitología y Biomedicina López-Neyra, (IPBLN-CSIC), Parque Tecnológico Ciencias de la Salud, Avenida Conocimiento s/n, Armilla, 18100 Granada, Spain
2Systemic Autoimmune Diseases Unit, Department of Internal Medicine, San Cecilio University Hospital (SCUH), Avenida Dr. Oloriz, no. 16, Granada 18012, Spain
3Department of Microbiology, University of Alabama at Birmingham, 1720 2nd Ave South, Birmingham, AL 35294, USA
4Department of Dermatology, SCUH, Avenida Dr. Oloriz, No. 16, Granada 18012, Spain

Received 9 May 2012; Revised 21 August 2012; Accepted 3 September 2012

Academic Editor: Eric F. Morand

Copyright © 2012 Sonia Garcia-Rodriguez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Cervera, “Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the ‘Euro-Lupus Project’,” Autoimmunity Reviews, vol. 5, no. 3, pp. 180–186, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Perl, “Pathogenic mechanisms in systemic lupus erythematosus,” Autoimmunity, vol. 43, no. 1, pp. 1–6, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. S. A. Jenks and I. Sanz, “Altered B cell receptor signaling in human systemic lupus erythematosus,” Autoimmunity Reviews, vol. 8, no. 3, pp. 209–213, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. J. C. Crispín, V. C. Kyttaris, C. Terhorst, and G. C. Tsokos, “T cells as therapeutic targets in SLE,” Nature Reviews Rheumatology, vol. 6, no. 6, pp. 317–325, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. G. C. Tsokos, “Systemic lupus erythematosus,” The New England Journal of Medicine, vol. 365, pp. 2110–2121, 2011. View at Google Scholar
  6. M. Nakou, G. Bertsias, I. Stagakis et al., “Gene network analysis of bone marrow mononuclear cells reveals activation of multiple kinase pathways in human systemic lupus erythematosus,” PLoS ONE, vol. 5, no. 10, Article ID e13351, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. M. M. Juntilla and G. A. Koretzky, “Critical roles of the PI3K/Akt signaling pathway in T cell development,” Immunology Letters, vol. 116, no. 2, pp. 104–110, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Finlay and D. A. Cantrell, “Metabolism, migration and memory in cytotoxic T cells,” Nature Reviews Immunology, vol. 11, no. 2, pp. 109–117, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Bononi, C. Agnoletto, E. De Marchi et al., “Protein kinases and phosphatases in the control of cell fate,” Enzyme Research, vol. 2011, Article ID 329098, 26 pages, 2011. View at Publisher · View at Google Scholar
  10. A. N. Macintyre, D. Finlay, G. Preston et al., “Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism,” Immunity, vol. 34, no. 2, pp. 224–236, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. T. E. Taher, K. Parikh, F. Flores-Borja et al., “Protein phosphorylation and kinome profiling reveal altered regulation of multiple signaling pathways in B lymphocytes from patients with systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 62, no. 8, pp. 2412–2423, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Gorelik and B. Richardson, “Key role of ERK pathway signaling in lupus,” Autoimmunity, vol. 43, no. 1, pp. 17–22, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Molad, M. Amit-Vasina, O. Bloch, E. Yona, and M. J. Rapoport, “Increased ERK and JNK activities correlate with disease activity in patients with systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 69, no. 1, pp. 175–180, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. A. H. Sawalha, M. Jeffries, R. Webb et al., “Defective T-cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation-sensitive genes similar to lupus patients,” Genes and Immunity, vol. 9, no. 4, pp. 368–378, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Krishnan, Y. T. Juang, B. Chowdhury et al., “Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells,” Journal of Immunology, vol. 181, no. 11, pp. 8145–8152, 2008. View at Google Scholar · View at Scopus
  16. S. A. Apostolidis, L. A. Lieberman, K. Kis-Toth et al., “The dysregulation of cytokine networks in systemic lupus erythematosus,” Journal of Interferon & Cytokine Research, vol. 31, pp. 769–779, 2011. View at Google Scholar
  17. N. Jacob and W. Stohl , “Cytokine disturbances in systemic lupus erythematosus,” Arthritis Research & Therapy, vol. 13, article 228, 2011. View at Google Scholar
  18. S. N. Kariuki and T. B. Niewold, “Genetic regulation of serum cytokines in systemic lupus erythematosus,” Translational Research, vol. 155, no. 3, pp. 109–117, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. D. L. Su, Z. M. Lu, M. N. Shen et al., “Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE,” Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 347141, 15 pages, 2012. View at Publisher · View at Google Scholar
  20. S. L. Yu, W. P. Kuan, C. K. Wong et al., “Immunopathological roles of cytokines, chemokines, signaling molecules, and pattern-recognition receptors in systemic lupus erythematosus,” Clinical and Developmental Immunology, vol. 2012, Article ID 715190, 14 pages, 2012. View at Publisher · View at Google Scholar
  21. J. Zhu and W. E. Paul, “Heterogeneity and plasticity of T helper cells,” Cell Research, vol. 20, no. 1, pp. 4–12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Nakayamada, H. Takahashi, Y. Kanno et al., “Helper T cell diversity and plasticity,” Current Opinion in Immunology, vol. 24, pp. 297–302, 2012. View at Google Scholar
  23. R. W. Y. Chan, F. M. M. Lai, E. K. M. Li et al., “Imbalance of Th1/Th2 transcription factors in patients with lupus nephritis,” Rheumatology, vol. 45, no. 8, pp. 951–957, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Garcia-Rodriguez, S. Arias-Santiago, R. Perandres-Lopez et al., “Increased gene expression of Toll-like receptor 4 on peripheral blood mononuclear cells in patients with psoriasis,” Journal of the European Academy of Dermatology and Venereology. In press. View at Publisher · View at Google Scholar
  25. B. H. Chung, H. J. Oh, S. G. Piao et al., “Clinical significance of the ratio between FOXP3 positive regulatory T cell and interleukin-17 secreting cell in renal allograft biopsies with acute T-cell-mediated rejection,” Immunology, vol. 136, no. 3, pp. 344–351, 2012. View at Google Scholar
  26. K. Miyake, M. Akahoshi, and H. Nakashima, “Th subset balance in lupus nephritis,” Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 980286, 7 pages, 2011. View at Publisher · View at Google Scholar
  27. M. S. Soyfoo, J. Roth, T. Vogl, R. Pochet, and G. Decaux, “Phagocyte-specific S100A8/A9 protein levels during disease exacerbations and infections in systemic lupus erythematosus,” Journal of Rheumatology, vol. 36, no. 10, pp. 2190–2194, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Lood, M. Stenström, H. Tydén et al., “Protein synthesis of the pro-inflammatory S100A8/A9 complex in plasmacytoid dendritic cells and cell surface S100A8/A9 on leukocyte subpopulations in systemic lupus erythematosus,” Arthritis Research and Therapy, vol. 13, no. 2, article R60, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. E. J. Pavon, S. Garcia-Rodriguez, E. Zumaquero et al., “Increased expression and phosphorylation of the two S100A9 isoforms in mononuclear cells from patients with systemic lupus erythematosus: a proteomic signature for circulating low-density granulocytes,” Journal of Proteomics, vol. 75, no. 6, pp. 1778–91, 2012. View at Google Scholar
  30. C. Bombardier, D. D. Gladman, M. B. Urowitz, D. Caron, and C. H. Chang, “Derivation of the SLEDAI: a disease activity index for lupus patients,” Arthritis and Rheumatism, vol. 35, no. 6, pp. 630–640, 1992. View at Publisher · View at Google Scholar · View at Scopus
  31. E. M. Tan, A. S. Cohen, and J. F. Fries, “The 1982 revised criteria for the classification of systemic lupus erythrematosus,” Arthritis and Rheumatism, vol. 25, no. 11, pp. 1271–1277, 1982. View at Google Scholar · View at Scopus
  32. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Zhu and W. E. Paul, “Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors,” Immunological Reviews, vol. 238, no. 1, pp. 247–262, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. J. B. Wing and S. Sakaguchi, “Multiple treg suppressive modules and their adaptability,” Frontiers in Immunology, vol. 3, p. 178, 2012. View at Google Scholar
  35. H. J. Haga, J. G. Brun, H. B. Berntzen, R. Cervera, M. Khamashta, and G. R. V. Hughes, “Calprotection in patients with systemic lupus erythematosus: relation to clinical and laboratory parameters of disease activity,” Lupus, vol. 2, no. 1, pp. 47–50, 1993. View at Google Scholar · View at Scopus
  36. L. Wei, G. Vahedi, H. W. Sun et al., “Discrete roles of STAT4 and STAT6 transcription factors in tuning epigenetic modifications and transcription during T helper cell differentiation,” Immunity, vol. 32, no. 6, pp. 840–851, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. R. J. Salmond, J. Emery, K. Okkenhaug, and R. Zamoyska, “MAPK, phosphatidylinositol 3-kinase, and mammalian target of rapamycin pathways converge at the level of ribosomal protein S6 phosphorylation to control metabolic signaling in CD8 T cells,” Journal of Immunology, vol. 183, no. 11, pp. 7388–7397, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. Q. Wan, L. Kozhaya, A. ElHed et al., “Cytokine signals through PI-3 kinase pathway modulate Th17 cytokine production by CCR6+ human memory T cells,” The Journal of Experimental Medicine, vol. 208, pp. 1875–1887, 2011. View at Google Scholar
  39. Y. Kurebayashi, S. Nagai, A. Ikejiri et al., “PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of RORgamma,” Cell Reports, vol. 1, pp. 360–373, 2012. View at Google Scholar
  40. S. Sauer, L. Bruno, A. Hertweck et al., “T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 22, pp. 7797–7802, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. Arimura, F. Shiroki, S. Kuwahara et al., “Akt is a neutral amplifier for Th cell differentiation,” The Journal of Biological Chemistry, vol. 279, no. 12, pp. 11408–11416, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Okkenhaug, D. T. Patton, A. Bilancio, F. Garçon, W. C. Rowan, and B. Vanhaesebroeck, “The p110δ isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells,” Journal of Immunology, vol. 177, no. 8, pp. 5122–5128, 2006. View at Google Scholar · View at Scopus
  43. A. Suarez-Fueyo, D. F. Barber, J. Martinez-Ara et al., “Enhanced phosphoinositide 3-kinase delta activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death,” The Journal of Immunology, vol. 187, pp. 2376–2385, 2011. View at Google Scholar
  44. J. Morel, R. Audo, M. Hahne, and B. Combe, “Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt,” The Journal of Biological Chemistry, vol. 280, no. 16, pp. 15709–15718, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Komatsuda, H. Wakui, K. Iwamoto et al., “Up-regulation of TRAIL mRNA expression in peripheral blood mononuclear cells from patients with active systemic lupus erythematosus,” Clinical Immunology, vol. 125, no. 1, pp. 26–29, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. S. C. Huang, H. F. Tsai, H. T. Tzeng, H. J. Liao, and P. N. Hsu, “Lipid raft assembly and LcK recruitment in TRAIL costimulation mediates NF-κB activation and T cell proliferation,” Journal of Immunology, vol. 186, no. 2, pp. 931–939, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. A. M. Fischer, C. D. Katayama, G. Pagès, J. Pouysségur, and S. M. Hedrick, “The role of Erk1 and Erk2 in multiple stages of T cell development,” Immunity, vol. 23, no. 4, pp. 431–443, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. A. von Kriegsheim, D. Baiocchi, M. Birtwistle et al., “Cell fate decisions are specified by the dynamic ERK interactome,” Nature Cell Biology, vol. 11, no. 12, pp. 1458–1464, 2009. View at Google Scholar · View at Scopus
  49. Y. Zhu and P. J. Bertics, “Chemoattractant-induced signaling via the Ras-ERK and PI3K-Akt networks, along with leukotriene C4 release, is dependent on the tyrosine kinase Lyn in IL-5- and IL-3-primed human blood eosinophils,” Journal of Immunology, vol. 186, no. 1, pp. 516–526, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. D. Arasappan, W. Tong, P. Mummaneni, H. Fang, and S. Amur, “Meta-analysis of microarray data using a pathway-based approach identifies a 37-gene expression signature for systemic lupus erythematosus in human peripheral blood mononuclear cells,” BMC Medicine, vol. 9, article 65, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. V. Gateva, J. K. Sandling, G. Hom et al., “A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus,” Nature Genetics, vol. 41, no. 11, pp. 1228–1233, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. M. O. Li and R. A. Flavell, “Contextual regulation of inflammation: a duet by transforming growth factor-β and interleukin-10,” Immunity, vol. 28, no. 4, pp. 468–476, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. W. Ouyang, S. Rutz, N. K. Crellin, P. A. Valdez, and S. G. Hymowitz, “Regulation and functions of the IL-10 family of cytokines in inflammation and disease,” Annual Review of Immunology, vol. 29, pp. 71–109, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Saraiva and A. O'Garra, “The regulation of IL-10 production by immune cells,” Nature Reviews Immunology, vol. 10, no. 3, pp. 170–181, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. N. A. Carter, R. Vasconcellos, E. C. Rosser et al., “Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells,” Journal of Immunology, vol. 186, no. 10, pp. 5569–5579, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Saraiva, J. R. Christensen, M. Veldhoen, T. L. Murphy, K. M. Murphy, and A. O'Garra, “Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose,” Immunity, vol. 31, no. 2, pp. 209–219, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. L. R. Grant, Z. J. Yao, C. M. Hedrich et al., “Stat4-dependent, T-bet-independent regulation of IL-10 in NK cells,” Genes and Immunity, vol. 9, no. 4, pp. 316–327, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. M. J. McGeachy, K. S. Bak-Jensen, Y. Chen et al., “TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell-mediated pathology,” Nature Immunology, vol. 8, no. 12, pp. 1390–1397, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Avagyan, F. Aguilo-Payeras, K. Kamezaki et al., “Quantitative trait mapping reveals a regulatory axis involving peroxisome proliferator-activated receptors, PRDM16, transforming growth factor-beta2 and FLT3 in hematopoiesis,” Blood, vol. 118, pp. 6078–6086, 2011. View at Google Scholar
  60. A. L. Astier, G. Beriou, T. M. Eisenhaure, S. M. Anderton, D. A. Hafler, and N. Hacohen, “RNA interference screen in primary human T cells reveals FLT3 as a modulator of IL-10 levels,” Journal of Immunology, vol. 184, no. 2, pp. 685–693, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. P. Lopez, C. Gutierrez, and A. Suarez, “IL-10 and TNFalpha genotypes in SLE,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 838390, 2010. View at Google Scholar
  62. T. Smallie, G. Ricchetti, N. J. Horwood, M. Feldmann, A. R. Clark, and L. M. Williams, “IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages,” Journal of Experimental Medicine, vol. 207, no. 10, pp. 2081–2088, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Zubiaur, O. Fernández, E. Ferrero et al., “CD38 is associated with lipid rafts and upon receptor stimulation leads to Akt/protein kinase B and Erk activation in the absence of the CD3-ζ immune receptor tyrosine-based activation motifs,” Journal of Biological Chemistry, vol. 277, no. 1, pp. 13–22, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. E. Zumaquero, P. Muñoz, M. Cobo et al., “Exosomes from human lymphoblastoid B cells express enzymatically active CD38 that is associated with signaling complexes containing CD81, Hsc-70 and Lyn,” Experimental Cell Research, vol. 316, no. 16, pp. 2692–2706, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. D. T. Patton, M. D. Wilson, W. C. Rowan, D. R. Soond, and K. Okkenhaug, “The PI3K p110δ regulates expression of CD38 on regulatory T cells,” PLoS ONE, vol. 6, no. 3, Article ID e17359, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. P. A. Blair, L. Y. Noreña, F. Flores-Borja et al., “CD19+CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients,” Immunity, vol. 32, no. 1, pp. 129–140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Chaudhry, R. M. Samstein, P. Treuting et al., “Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation,” Immunity, vol. 34, no. 4, pp. 566–578, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Huber, N. Gagliani, E. Esplugues et al., “Th17 cells express interleukin-10 receptor and are controlled by Foxp3- and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner,” Immunity, vol. 34, no. 4, pp. 554–565, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Y. Rudensky, “Regulatory T cells and Foxp3,” Immunological Reviews, vol. 241, no. 1, pp. 260–268, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Barreto, R. C. Ferreira, L. Lourenço et al., “Low frequency of CD4+CD25+ Treg in SLE patients: a heritable trait associated with CTLA4 and TGFβ gene variants,” BMC Immunology, vol. 10, article 5, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. M. J. L. Suggs, V. Majithia, R. E. Lewis, and J. M. Cruse, “HLA DRB1*1503 allelic haplotype predominance and associated immunodysregulation in systemic lupus erythematosus,” Experimental and Molecular Pathology, vol. 91, no. 2, pp. 548–562, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. N. A. Azab, I. H. Bassyouni, Y. Emad, G. A. Abd El-Wahab, G. Hamdy, and M. A. Mashahit, “CD4+CD25+ regulatory T cells (TREG) in Systemic Lupus Erythematosus (SLE) patients: the possible influence of treatment with corticosteroids,” Clinical Immunology, vol. 127, no. 2, pp. 151–157, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. C. Prado, J. Gómez, P. López, B. de Paz, C. Gutiérrez, and A. Suárez, “Dexamethasone upregulates FOXP3 expression without increasing regulatory activity,” Immunobiology, vol. 216, no. 3, pp. 386–392, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Sbiera, T. Dexneit, S. D. Reichardt et al., “Influence of short-term glucocorticoid therapy on regulatory T cells in vivo,” PLoS ONE, vol. 6, Article ID e24345, 2011. View at Google Scholar
  75. W. H. Abdulahad, A. M. H. Boots, and C. G. M. Kallenberg, “FoxP3+ CD4+ T cells in systemic autoimmune diseases: the delicate balance between true regulatory T cells and effector Th-17 cells,” Rheumatology, vol. 50, no. 4, pp. 646–656, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. K. M. Murphy and B. Stockinger, “Effector T cell plasticity: flexibility in the face of changing circumstances,” Nature Immunology, vol. 11, no. 8, pp. 674–680, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. X. Valencia, C. Yarboro, G. Illei, and P. E. Lipsky, “Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus,” Journal of Immunology, vol. 178, no. 4, pp. 2579–2588, 2007. View at Google Scholar · View at Scopus
  78. J. Ma, J. Yu, X. Tao, L. Cai, J. Wang, and S. G. Zheng, “The imbalance between regulatory and IL-17-secreting CD4+ T cells in lupus patients,” Clinical Rheumatology, vol. 29, no. 11, pp. 1251–1258, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. Q. Xing, B. Wang, H. Su, J. Cui, and J. Li, “Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis,” Rheumatology International, vol. 32, no. 4, pp. 949–958, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Chapoval, P. Dasgupta, N. J. Dorsey, and A. D. Keegan, “Regulation of the T helper cell type 2 (Th2)/T regulatory cell (Treg) balance by IL-4 and STAT6,” Journal of Leukocyte Biology, vol. 87, no. 6, pp. 1011–1018, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. Y. Wang, M. A. Su, and Y. Y. Wan, “An essential role of the transcription factor GATA-3 for the function of regulatory T cells,” Immunity, vol. 35, pp. 337–348, 2011. View at Google Scholar
  82. K. Shah, W. W. Lee, S. H. Lee et al., “Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus,” Arthritis Research and Therapy, vol. 12, no. 2, article R53, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. F. Sallusto, E. Kremmer, B. Palermo et al., “Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells,” European Journal of Immunology, vol. 29, pp. 2037–2045, 1999. View at Google Scholar
  84. C. Prado, B. de Paz, J. Gomez et al., “Glucocorticoids enhance Th17/Th1 imbalance and signal transducer and activator of transcription 3 expression in systemic lupus erythematosus patients,” Rheumatology, vol. 50, pp. 1794–1801, 2011. View at Google Scholar
  85. D. A. Horwitz, “Identity of mysterious CD4+CD25-Foxp3+ cells in SLE,” Arthritis Research & Therapy, vol. 12, no. 1, p. 101, 2010. View at Google Scholar · View at Scopus
  86. X. Zhou, S. Bailey-Bucktrout, L. T. Jeker, and J. A. Bluestone, “Plasticity of CD4+ FoxP3+ T cells,” Current Opinion in Immunology, vol. 21, no. 3, pp. 281–285, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. L. Lu, X. Zhou, J. Wang, S. G. Zheng, and D. A. Horwitz, “Characterization of protective human CD4CD25 FOXP3 regulatory T cells generated with IL-2, TGF-β and retinoic acid,” PloS ONE, vol. 5, no. 12, p. e15150, 2010. View at Google Scholar · View at Scopus
  88. M. B. Hale, P. O. Krutzik, S. S. Samra, J. M. Crane, and G. P. Nolan, “Stage dependent aberrant regulation of cytokine-STAT signaling in murine systemic lupus erythematosus,” PLoS ONE, vol. 4, no. 8, Article ID e6756, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. H. Cash, M. Relle, J. Menke et al., “Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Fas lpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus,” Journal of Rheumatology, vol. 37, no. 1, pp. 60–70, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. H. Y. Chun, J. W. Chung, H. A. Kim et al., “Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus,” Journal of Clinical Immunology, vol. 27, no. 5, pp. 461–466, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. S. Hu, W. Xiao, F. Kong, D. Ke, R. Qin, and M. Su, “Regulatory T cells and their molecular markers in peripheral blood of the patients with systemic lupus erythematosus,” Journal of Huazhong University of Science and Technology, vol. 28, no. 5, pp. 549–552, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. K. Ohl and K. Tenbrock, “Inflammatory cytokines in systemic lupus erythematosus,” Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 432595, 14 pages, 2011. View at Publisher · View at Google Scholar
  93. A. Sabry, H. sheashaa, A. El-husseini et al., “Proinflammatory cytokines (TNF-α and IL-6) in Egyptian patients with SLE: its correlation with disease activity,” Cytokine, vol. 35, no. 3-4, pp. 148–153, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. W. E. Naugler and M. Karin, “The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer,” Trends in Molecular Medicine, vol. 14, no. 3, pp. 109–119, 2008. View at Publisher · View at Google Scholar · View at Scopus
  95. E. Sonoda, R. Matsumoto, Y. Hitoshi et al., “Transforming growth factor β induces IgA production and acts additively with interleukin 5 for IgA production,” The Journal of Experimental Medicine, vol. 170, no. 4, pp. 1415–1420, 1989. View at Google Scholar · View at Scopus
  96. T. Hayashi, “Therapeutic strategies for SLE involving cytokines: mechanism-oriented therapies especially IFN-λ targeting gene therapy,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 461641, 19 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. L. D. Erickson, T. M. Foy, and T. J. Waldschmidt, “Murine B1 B cells require IL-5 for optimal T cell-dependent activation,” Journal of Immunology, vol. 166, no. 3, pp. 1531–1539, 2001. View at Google Scholar · View at Scopus
  98. F. Martin and J. F. Kearney, “B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a natural immune memory,” Immunological Reviews, vol. 175, pp. 70–79, 2000. View at Publisher · View at Google Scholar · View at Scopus
  99. S. Koyasu and K. Moro, “Type 2 innate immune responses and the natural helper cell,” Immunology, vol. 132, no. 4, pp. 475–481, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. X. Wen, D. Zhang, Y. Kikuchi et al., “Transgene-mediated hyper-expression of IL-5 inhibits autoimmune disease but increases the risk of B cell chronic lymphocytic leukemia in a model of murine lupus,” European Journal of Immunology, vol. 34, no. 10, pp. 2740–2749, 2004. View at Publisher · View at Google Scholar · View at Scopus
  101. N. V. Valeyev, C. Hundhausen, Y. Umezawa et al., “A systems model for immune cell interactions unravels the mechanism of inflammation in human skin,” PLoS Computational Biology, vol. 6, no. 12, Article ID e1001024, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. E. R. Capper, J. K. Maskill, C. Gordon, and A. I. F. Blakemore, “Interleukin (IL)-10, IL-1ra and IL-12 profiles in active and quiescent systemic lupus erythematosus: could longitudinal studies reveal patient subgroups of differing pathology?” Clinical and Experimental Immunology, vol. 138, no. 2, pp. 348–356, 2004. View at Publisher · View at Google Scholar · View at Scopus
  103. B. Rhodes, J. Meek, J. C. Whittaker, and T. J. Vyse, “Quantification of the genetic component of basal C-reactive protein expression in SLE nuclear families,” Annals of Human Genetics, vol. 72, no. 5, pp. 611–620, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. E. Meinl, D. Lengenfelder, N. Blank, R. Pirzer, L. Barata, and C. Hivroz, “Differential requirement of ZAP-70 for CD2-mediated activation pathways of mature T cells,” Journal of Immunology, vol. 165, no. 7, pp. 3578–3583, 2000. View at Google Scholar · View at Scopus
  105. D. Foell, H. Wittkowski, T. Vogl, and J. Roth, “S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules,” Journal of Leukocyte Biology, vol. 81, no. 1, pp. 28–37, 2007. View at Publisher · View at Google Scholar · View at Scopus
  106. C. F. Urban, D. Ermert, M. Schmid et al., “Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans,” PLoS Pathogens, vol. 5, no. 10, Article ID e1000639, 2009. View at Publisher · View at Google Scholar · View at Scopus